TRIUMF provides a unique infrastructure (7 cyclotrons) for producing medical radionuclides with protons for imaging and therapy (theranostic). TR-13 (13 MeV) cyclotron is a working horse of the TRIUMF Life Sciences Division (LSD), which is used for the production of well-established imaging radionuclides e.g. ¹⁸F and ¹¹C, as well as several imaging radiometals including but not limited to ⁶⁸Ga,⁴⁴Sc, ⁴⁵Ti, and ⁸⁹Zr and few therapeutic radionuclides e.g. ¹¹⁹Sb, ^197m+gHg, ¹⁶⁵Er, ¹⁰³Pd. Besides TR-13, LS is actively utilizing several other TRIUMF accelerators, including Isotope Separator and Accelerator (ISAC) (production of ^209/211At, ²²⁵Ra/²²⁵Ac, ²²⁶Ac, ¹⁵⁵Tb, ¹⁶⁵Er), Isotopes Production Facility (IPF) for spallation reaction on thorium target for production of several emerging therapeutic radionuclides (e.g. ²²⁵Ac). The status of utilization of these facilities and potential future production capabilities, including Advanced Rare Isotope Laboratory (ARIEL) proton and electron beamlines and Institute for Advanced Medical Isotopes (IAMI).

Presenter Biography:
Dr. Radchenko is a Research Scientist at TRIUMF and an adjunct professor at the University of British Columbia, Chemistry Department with the main research focus on the production and application of therapeutic radionuclides for Targeted Radionuclide Therapy (TRT). Radiochemist by training graduated from Saint-Petersburg State Technical University (Russian Federation) in collaboration with the Joint Institute for Nuclear Research (JINR) in Dubna (Russian Federation). He received his Ph.D. from Johannes-Gutenberg University Mainz (Germany) in 2013 with a thesis focused on the design of production of a promising radionuclide for immuno-PET: Nb-90. Further, realizing the potential of targeted therapy he pursued a postdoctoral position at Los Alamos National Laboratory, NM, USA, where he worked as a part of the tri-lab effort on the production of Ac-225 from spallation of thorium with high-energy protons. Besides, the Ac-225 production effort, he also worked on other efforts including extraction of valuable medical radionuclides from irradiated thorium targets (e.g. Ra-223/224/225, Pa-230, Ru-103/Rh-103m, Ag-111), design of production alternative for low energy slot at Isotope Production Facility at LANL and others. He published over 90 scientific papers in peer-reviewed journals and was a guest editor on special issues on alpha and Auger emitters for Targeted Therapy.

Author